Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS

Summary

This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 or influenza (A or B). The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose of AVM0703 in these ARDS patients.

Timeline

Start

2026-12-01

Primary completion

2031-12-01

Completion

2032-03-01

Drugs

Indications